Good Evening Market Enthusiast,

When a reputable analyst raises their target to $10.27, which is 550%+ upside from current levels — the market takes notice.

But here's what everyone is missing:

This isn't just another biotech story. This is first-in-class telomere targeting — the only direct approach of its kind in clinical trials.

The data that dropped this week: 
✅ 17.8-month median survival in heavily pretreated NSCLC patients 
✅ 95% confidence interval lower bound: 12.5 months 
✅ Confirmed 30%+ tumor reduction after 20+ months of therapy

Compare that to standard chemotherapy: 5-6 months survival.

The science? Validated as "de-risked." The partnerships? Massive. The regulatory path? FDA Fast Track designation secured.

Tomorrow at 8AM EST, we reveal the company behind the breakthrough that's rewriting cancer survival curves.

⏳ This isn't speculation — it's execution meeting opportunity.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Paid Promotion. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is fina.ncial advice. Momentum Media LLC is not an analyst, st.o.ck broker, fina.ncial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.